We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of a Polymorphism in Patients With Prostate Cancer

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00900185
First Posted: May 12, 2009
Last Update Posted: April 30, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
National Cancer Institute (NCI)
May 9, 2009
May 12, 2009
April 30, 2015
Not Provided
Not Provided
Frequency of D104N COL18A1 polymorphism in patients with prostate cancer and in healthy participants
Same as current
Complete list of historical versions of study NCT00900185 on ClinicalTrials.gov Archive Site
Frequency of D104N COL18A1 polymorphism in African-American patients with prostate cancer and in healthy participants
Same as current
Not Provided
Not Provided
 
Study of a Polymorphism in Patients With Prostate Cancer
Retrospective Analysis of Endostatin Genotype in Prostate Cancer Patients to Assess the Association of a Single Nucleotide Polymorphism (D104N) in Endostatin and Prostate Cancer

RATIONALE: Studying samples of blood from patients with cancer and from healthy participants in the laboratory may help doctors learn more about changes that may occur in DNA.

PURPOSE: This laboratory study is looking at blood samples from patients with prostate cancer and from healthy participants to identify a polymorphism that may help in the study of prostate cancer.

OBJECTIVES:

Primary

  • Determine the incidence of the D104N COL18A1 polymorphism in patients with prostate cancer.

Secondary

  • Determine the incidence of this polymorphism in African-American patients with prostate cancer.

OUTLINE: This is a retrospective, multicenter study.

DNA is extracted from preexisting serum samples and polymerase chain reaction is performed to determine the genotype pattern.

PROJECTED ACCRUAL: A total of 500 patients and 250 healthy participants will be accrued for this study.

Observational
Not Provided
Not Provided
Not Provided
Not Provided
Not Provided
Prostate Cancer
  • Genetic: mutation analysis
  • Genetic: polymerase chain reaction
  • Genetic: polymorphism analysis
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
750
Not Provided
Not Provided

DISEASE CHARACTERISTICS:

  • Diagnosis of prostate cancer OR healthy participant
  • Patient enrolled on an IRB-approved clinical trial at the National Cancer Institute or Northwestern University, including, but not limited to, any of the following:

    • NCI-99-C-0052
    • NCI-95-C-0178
    • NCI-00-C-003
    • NCI-00-C-0080

PATIENT CHARACTERISTICS:

  • Not specified

PRIOR CONCURRENT THERAPY:

  • Not specified
Sexes Eligible for Study: Male
Child, Adult, Senior
Yes
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
 
NCT00900185
CDR0000304552
NCI-03-C-0153
NU-98U2
Not Provided
Not Provided
Not Provided
Not Provided
National Cancer Institute (NCI)
Not Provided
Study Chair: William D. Figg, PharmD National Cancer Institute (NCI)
National Cancer Institute (NCI)
February 2007